Anzeige
Meldung des Tages: Von KI-Energie bis Waste-to-Energy: Global Power erweitert seine Position im globalen Infrastrukturmarkt

Nuvalent News

Aktie
WKN:  A3CWDU ISIN:  US6707031075 US-Symbol:  NUVL Branche:  Biotechnologie Land:  USA
108,27 $
+0,03 $
+0,03%
91,955 € 20.04.26
Depot/Watchlist
Marktkapitalisierung *
5,06 Mrd. €
Streubesitz
-
KGV
-18,06
Index-Zuordnung
-

Nuvalent News

17.04.26 - PR Newswire
New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026
New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026 PR Newswire
07.04.26 - PR Newswire
Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC
Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-​treated Advanced ALK-​positive NSCLC PR Newswire
17.03.26 - PR Newswire
Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026
Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026 PR Newswire
26.02.26 - PR Newswire
Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results
Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results PR Newswire
05.02.26 - PR Newswire
Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 PR Newswire
12.01.26 - PR Newswire
Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones
Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones PR Newswire
22.12.25 - PR Newswire
Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference
Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire
10.12.25 - PR Newswire
Nuvalent Appoints Ron Squarer to Board of Directors
Nuvalent Appoints Ron Squarer to Board of Directors PR Newswire
26.11.25 - PR Newswire
Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference
Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference PR Newswire
24.11.25 - PR Newswire
Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders
Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders PR Newswire
19.11.25 - PR Newswire
Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC
Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-​treated Patients with Advanced ROS1-positive NSCLC PR Newswire
18.11.25 - PR Newswire
Nuvalent Announces Pricing of Public Offering of Common Stock
Nuvalent Announces Pricing of Public Offering of Common Stock PR Newswire
17.11.25 - PR Newswire
Nuvalent Announces Public Offering of Common Stock
Nuvalent Announces Public Offering of Common Stock PR Newswire
17.11.25 - PR Newswire
Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC
Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-​treated Patients with Advanced ALK-​positive NSCLC PR Newswire
14.11.25 - PR Newswire
Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib
Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-​treated Patients with Advanced ALK-​positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib PR Newswire
04.11.25 - PR Newswire
Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer
Nuvalent to Present Patient-​Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung ...
30.10.25 - PR Newswire
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results PR Newswire
18.10.25 - PR Newswire
Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025
Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-​positive Solid Tumors Beyond NSCLC at ESMO 2025 PR Newswire
13.10.25 - PR Newswire
Nuvalent to Present New Preclinical Data for HER2-Selective Inhibitor, NVL-330, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Nuvalent to Present New Preclinical Data for HER2-Selective Inhibitor, NVL-330, at AACR-​NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics PR ...
24.09.25 - PR Newswire
Nuvalent to Participate in the UBS 2025 Virtual Oncology Day
Nuvalent to Participate in the UBS 2025 Virtual Oncology Day PR Newswire

Newssuche

Videos

newspaper
20.04.26 -1,10%
Technical Trading: GBP Long im Trend
GBP/USD Long Typ: Open End Turbo WKN: VV7A4S Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »